Crossmark

Treatment adherence and clinical outcomes of osimertinib in minority patients with advanced EGFR mutated NSCLC

Published Online: 2026-01-27

Authors

Lee, Matthew

Song, Junmin

Miao, Emily

Alicea, Daniel S.

Zhang, Chenxin

Xue, Xiaonan

Tuckman, Steven

Yang, Jihua

D’Aiello, Angelica

Gucalp, Rasim

Stiles, Brendon

Ohri, Nitin

Halmos, Balazs

Cheng, Haiying
License Information

Text and Data Mining valid from 2026-01-27

Version of Record valid from 2026-02-27
More Information

Article History

Received: 20 August 2025

Accepted: 15 December 2025

First Online: 27 January 2026

Competing interests

: H. Cheng and J. Yang received research support from AstraZeneca. The other authors declare no financial or non-financial competing interests.

Document is current